Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

https://doi.org/10.1182/blood-2019-125495

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD

Blood (2018) 132 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2018-99-112235

Published: 2018

Journal Articles

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Blood (2016) 128 (22): 1102.

https://doi.org/10.1182/blood.V128.22.1102.1102

Published: 2016

Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood (2014) 124 (21): 4457.

https://doi.org/10.1182/blood.V124.21.4457.4457

Published: 2014

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

Arnon P. Kater, MD PhD, Sanne H. Tonino, MD, PhD, Marie Jose Kersten, MD, PhD, Anton Hagenbeek, MD, PhD, Marjolein Spiering, Msc, Marinus H van Oers, MD PhD, Yan Xin, PhD, Srinivasan Ramanathan, PhD, Maria Aiello, MA, Susie Jun, MD, PhD

Blood (2013) 122 (21): 2881.

https://doi.org/10.1182/blood.V122.21.2881.2881

Published: 2013

Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Blood (2013) 122 (21): 509.

https://doi.org/10.1182/blood.V122.21.509.509

Published: 2013

Journal Articles

C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia

Diana Wouters, Femke Stephan, Paul Strengers, Masja de Haas, Conny Brouwer, Anton Hagenbeek, Marinus H. J. van Oers, Sacha Zeerleder

Blood (2013) 121 (7): 1242–1244.

https://doi.org/10.1182/blood-2012-11-467209

Published: 2013

Journal Articles

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Blood (2012) 119 (16): 3698–3704.

https://doi.org/10.1182/blood-2011-09-378323

Published: 2012

Includes: Supplemental data

Journal Articles

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Diana Wouters, PhD, Stephan Femke, Masja de Haas, MD, PhD, Conny Brouwer, Paul Strengers, MD PhD, Anton Hagenbeek, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Sacha Zeerleder, MD PhD

Blood (2011) 118 (21): 716.

https://doi.org/10.1182/blood.V118.21.716.716

Published: 2011

Journal Articles

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Blood (2011) 117 (26): 7070–7078.

https://doi.org/10.1182/blood-2011-04-345256

Published: 2011

Includes: Supplemental data

Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Blood (2010) 116 (21): 1788.

https://doi.org/10.1182/blood.V116.21.1788.1788

Published: 2010

Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Anton Hagenbeek, MD, PhD, John Radford, MD, Achiel Van Hoof, MD, Umberto Vitolo, MD, Ama Z.S. Rohatiner, MD, Gilles Salles, MD, PhD, Pierre Soubeyran, MD, PhD, Herve Tilly, MD, Angelika Bischof Delaloye, MD, Wim L.J. van Putten, MSc, Franck Morschhauser, MD, PhD

Blood (2010) 116 (21): 594.

https://doi.org/10.1182/blood.V116.21.594.594

Published: 2010

Journal Articles

Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.

Anton Hagenbeek, Luis Fayad, Vincent Delwail, Jean Francois Rossi, Eric Jacobsen, Kazimierz Kuliczkowski, Brian K Link, Lauren Pinter-Brown, John Radford, Andrzej Hellmann, Eve Gallop-Evans, Ira Gupta, Michael Arning, Kamilla Begtrup, Martin Schultz, Bo Bang, Charlotte A Russell, Myron S Czuczman

Blood (2009) 114 (22): 935.

https://doi.org/10.1182/blood.V114.22.935.935

Published: 2009

Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

Blood (2008) 112 (11): 2002.

https://doi.org/10.1182/blood.V112.11.2002.2002

Published: 2008

Journal Articles

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Liliana Baila, MD, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek

Blood (2008) 112 (11): 836.

https://doi.org/10.1182/blood.V112.11.836.836

Published: 2008

Journal Articles

Response: Multiple administrations of the fully human monoclonal antibody Ofatumumab

Anton Hagenbeek

Blood (2008) 112 (6): 2585.

https://doi.org/10.1182/blood-2008-07-166066

Published: 2008

Journal Articles

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Flensburg, Jørgen Petersen, Nedjad Losic, John Radford

Blood (2008) 111 (12): 5486–5495.

https://doi.org/10.1182/blood-2007-10-117671

Published: 2008

Journal Articles

Dosimetric Analysis of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Given as Consolidation of First Remission in Patients with Advanced-Stage Follicular Lymphoma in the International Phase 3 First-Line Indolent Trial (FIT).

Angelika Bischof-Delaloye, Cristian Antonescu, Anton Hagenbeek

Blood (2007) 110 (11): 3415.

https://doi.org/10.1182/blood.V110.11.3415.3415

Published: 2007

NARROW

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Response: Multiple administrations of the fully human monoclonal antibody Ofatumumab

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Dosimetric Analysis of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Given as Consolidation of First Remission in Patients with Advanced-Stage Follicular Lymphoma in the International Phase 3 First-Line Indolent Trial (FIT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only